Review examines the promise and limits of microRNAs in periodontitis diagnosis and alveolar bone regeneration research
Background: Studying periodontitis through both bacteria and host responses
MicroRNA (miRNA)-based diagnosis and regenerative treatment for periodontitis are promising, but validation supporting clinical use remains insufficient. A review published in the international journal Frontiers in Immunology brings together diagnostic candidates, regulation of bone resorption, stem-cell osteogenic differentiation, and RNA delivery technologies to summarize progress and limitations in previous studies. It is a literature review proposing research directions toward precision periodontal care, rather than a study newly demonstrating treatment efficacy in patients.
Periodontitis is a chronic inflammatory disease that damages the tissues supporting the teeth and the alveolar bone and can lead to tooth loss as it progresses. Both an imbalance in the subgingival microbial community and the host immune and inflammatory responses contribute to disease onset and progression. This has prompted research into regulating tissue-damaging host responses alongside bacterial control.
miRNAs are small non-protein-coding RNAs. They regulate gene expression by binding to target messenger RNAs (mRNAs), suppressing translation or inducing degradation. In periodontal tissues, they have been reported to participate in inflammatory responses, the formation of bone-resorbing osteoclasts, and stem-cell osteogenic differentiation.
Key findings: Repeatedly observed diagnostic candidates and cell-specific effects
The review identifies miR-146a, miR-155, and miR-223 as promising diagnostic candidates whose increased expression has been observed repeatedly across multiple studies. They can be detected in saliva and gingival crevicular fluid—the fluid collected from between the teeth and gums—and are being studied for noninvasive testing. However, an association between expression levels and disease does not by itself establish early diagnostic capability. Many studies are small and cross-sectional, and independent validation and clinical decision thresholds are lacking. Whether these miRNAs can predict disease progression remains a question for further investigation.
Research on bone resorption addresses the regulatory relationship between receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG). When RANKL binds to its receptor RANK, it promotes osteoclast formation and bone resorption; OPG blocks this binding. Several miRNAs participate in this signaling system, but their effects differ in direction. The evidence comes mainly from cell and small-animal studies, so it cannot be interpreted as showing that a particular miRNA combination halted alveolar bone loss in humans.
Osteogenic differentiation of periodontal ligament stem cells (PDLSCs) is another target for regulation. Differences between cell types and environments are crucial: the review notes that miR-21 has been reported to have different effects on osteogenic differentiation in bone marrow-derived stem cells and PDLSCs. Mechanical stimulation also influences its effects. Increased expression alone is therefore insufficient to determine whether a miRNA should be inhibited or supplemented as a therapeutic target.
Significance and outlook: The promise of delivery technologies and the limits of preclinical evidence
Therapeutic approaches include anti-miRNA inhibitors (anti-miRs), which suppress the function of specific miRNAs, and miRNA mimics, which supplement their function. In the preclinical studies reviewed, delivery using vehicles such as nanoparticles or hydrogels was reported to help reduce inflammation and support alveolar bone recovery. These delivery technologies were developed and evaluated in individual prior studies.
Challenges for clinical translation include protecting RNA from degradation, delivering it to target cells, and reducing off-target gene suppression. The effects of patient-specific factors, including smoking, diabetes, and medications, on miRNA profiles must also be considered. Long-term safety and efficacy relative to existing treatments remain to be evaluated. Evidence concentrated in cell and small-animal studies must be strengthened, and measurement and administration methods standardized, to assess the potential for personalized diagnosis and regenerative treatment. Current evidence does not establish therapeutic efficacy in humans or demonstrate that these approaches can replace surgery.
Further details are available in the review full text provided by Europe PMC and the bibliographic record and abstract on PubMed.
Dysregulated host-microbe interactions are a hallmark of periodontal disease (PD), a chronic inflammatory condition that causes progressive alveolar bone resorption and tooth loss. MicroRNAs (miRNAs) have become important epigenetic regulators, offering new ways to understand disease pathophysiology and to provide tailored treatments. The current analysis uniquely synthesizes pathogen-specific miRNA signatures, modulation of the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)/Osteoprotegerin (OPG) axis, periodontal ligament stem cells (PDLSCs) osteogenesis, and enhanced delivery platforms into a coherent precision medicine framework, in contrast to other studies that examined these areas independently. We investigate the role of miRNAs in PD, assess their potential as non-invasive diagnostic biomarkers, and review novel therapeutic approaches targeting these molecules.
For diagnostic development, researchers could design studies that repeatedly measure salivary and gingival crevicular fluid miRNAs in patients undergoing periodontal examinations and assess whether adding these measurements to existing tests better explains disease activity or treatment response. Accounting for confounding factors such as smoking and diabetes, and reproducing findings in separate patient groups, would be necessary to establish criteria suitable for clinical decisions. Treatment development requires testing not only whether local delivery vehicles protect RNA, but also which cells they reach and whether they have opposing effects on inflammation suppression and osteogenic differentiation. This review outlines research questions for evaluating diagnostic candidates and delivery technologies together. Long-term safety and efficacy compared with existing treatments still need to be established before clinical use.